Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 6/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632747 | 0.87 | DRD4 (0.54) | RHEBTRPA1DRD2DRD4DRD3 | |
| SCHEMBL746079 | 0.82 | DRD4 (0.63) | RHEBSLC6A4HTR2CDRD2DRD4 | |
| SCHEMBL29415608 | 0.82 | DRD4 (0.63) | RHEBSLC6A4HTR2CDRD2DRD4 | |
| SCHEMBL12821455 | 0.81 | RHEB (0.59) | RHEBSLC6A4DRD2DRD4DRD3 | |
| SCHEMBL12821465 | 0.81 | RHEB (0.54) | RHEBHTR2CDRD2DRD4DRD3 | |
| SCHEMBL20535781 | 0.78 | RHEB (1.00) | RHEBSLC6A4TRPA1 | |
| SCHEMBL20536492 | 0.78 | RHEB (1.00) | RHEBTRPA1 | |
| Indole SCHEMBL28308979 | 0.76 | DRD4 (0.56) | SLC6A4HTR2CTRPA1DRD2DRD4 | |
| SCHEMBL8546338 | 0.75 | MAPK14 (0.43) | RHEBSLC6A4HTR2CHTR2BDRD2 | |
| Pyridine SCHEMBL28519653 | 0.75 | DRD4 (0.55) | HTR2CDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | RHEB 2503/4885SLC6A4 4266/4885HTR2C 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.